publication venue for
- IS26-mediated amplification of blaOXA-1 and blaCTX-M-15 with concurrent outer membrane porin disruption associated with de novo carbapenem resistance in a recurrent bacteraemia cohort.. 76:385-395. 2020
- Constitutive expression of the cryptic vanGCd operon promotes vancomycin resistance in Clostridioides difficile clinical isolates. 75:859-867. 2020
- Predicting the risk of nephrotoxicity in patients receiving colistimethate sodium: a multicentre, retrospective, cohort study. 71:3585-3587. 2016
- Novel transferable erm(46) determinant responsible for emerging macrolide resistance in Rhodococcus equi. 71:1746-1746. 2016
- Novel transferable erm(46) determinant responsible for emerging macrolide resistance in Rhodococcus equi. 70:3184-3190. 2015
- Gastrointestinal localization of metronidazole by a lactobacilli-inspired tetramic acid motif improves treatment outcomes in the hamster model of Clostridium difficile infection. 70:3061-3069. 2015
- A novel alanine to serine substitution mutation in SoxS induces overexpression of efflux pumps and contributes to multidrug resistance in clinical Escherichia coli isolates. 70:2228-2233. 2015
- The membrane as a target for controlling hypervirulent Clostridium difficile infections. 68:806-815. 2013
- Novel anti-Cryptosporidium activity of known drugs identified by high-throughput screening against parasite fatty acyl-CoA binding protein (ACBP). 67:609-617. 2012
- In vitro antimicrobial studies of silver carbene complexes: activity of free and nanoparticle carbene formulations against clinical isolates of pathogenic bacteria. 67:138-148. 2012
- Reutericyclin and related analogues kill stationary phase Clostridium difficile at achievable colonic concentrations. 66:1773-1776. 2011
- A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents. 62:1037-1045. 2008
- In vivo transfer of high-level mupirocin resistance from Staphylococcus epidermidis to methicillin-resistant Staphylococcus aureus associated with failure of mupirocin prophylaxis. 56:1166-1168. 2005
- Anti-staphylococcal activity of indolmycin, a potential topical agent for control of staphylococcal infections. 54:549-552. 2004
- The isoleucyl-tRNA synthetase mutation V588F conferring mupirocin resistance in glycopeptide-intermediate Staphylococcus aureus is not associated with a significant fitness burden. 53:102-104. 2003